Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Current Liabilities (2016 - 2025)

Spyre Therapeutics' Total Current Liabilities history spans 11 years, with the latest figure at $58.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 8.56% year-over-year to $58.7 million; the TTM value through Dec 2025 reached $58.7 million, up 8.56%, while the annual FY2025 figure was $58.7 million, 8.56% up from the prior year.
  • Total Current Liabilities reached $58.7 million in Q4 2025 per SYRE's latest filing, up from $46.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $232.2 million in Q2 2023 to a low of $12.6 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $45.7 million, with a median of $32.2 million recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 1364.09% in 2023, then plummeted 90.47% in 2024.
  • A 5-year view of Total Current Liabilities shows it stood at $20.1 million in 2021, then fell by 27.24% to $14.7 million in 2022, then soared by 118.19% to $32.0 million in 2023, then soared by 69.05% to $54.1 million in 2024, then rose by 8.56% to $58.7 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Total Current Liabilities are $58.7 million (Q4 2025), $46.3 million (Q3 2025), and $83.1 million (Q2 2025).